ClinicalTrials.gg
RecruitingNCT06452849Updated Jun 11, 2024

Amygdala and dLPFC MRI-TIS for Depression in Adolescents

An interventional study of Nervio-X in Major Depressive Disorder, sponsored by Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University. Recruiting at 1 site in China. Open to participants aged 14 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-06-11.

Sponsored by Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
14 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 207 studies in Depressive Disorder, Major with a site in China — 75 open to participants now, 77 under way, 5 of them phase 3. Depressive Disorder, Major · China.

Planned enrollment
128th of 174
60 · median 120
Started
2024
with 15 others
No phase
100 of 207
49 open now
Primary completion
2025-04
later than 19 of 76 live
Registered
144th of 207
by date

Among the 207 studies in Depressive Disorder, Major with a site in China, this one is the 128th largest by planned enrollment of the 174 interventional ones that give a count, is one of 16 that started in 2024, is one of 100 with no phase, reaches primary completion later than 19 of the 76 other live ones, and was the 144th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

75 of the 207 studies in Depressive Disorder, Major with a site in China are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 14 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Depressive Disorder, Major with a site in China, or all of them as a file.
02

Study summary

The study utilizes a non-invasive deep brain stimulation (temporal interference, TI) technique primarily targeting the amygdala to preliminarily explore the clinical efficacy and potential mechanisms of MRI-compatible TI technology in regulating the amygdala in adolescent depressive disorders.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Adolescents
  • Deep Brain Stimulation
  • Major Depressive Disorder
  • Temporal Interference
  • Amygdala
04

Who can participate

Ages eligible
14 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be aged between 14 and 18, with no gender restrictions;
  • A diagnosis of depression made by the study physician based on the (DSM-5);
  • HAMD-17 score of 17 or higher;
  • Participants must not have changed their antidepressant medication regimen from 30 days prior to signing the form through the duration of the experiment;
  • Eligible individuals or their authorized representatives must demonstrate, as assessed by the study physician, a comprehensive understanding of the study's objectives and procedures, be capable of adhering to the requirements set forth in the study protocol, and provide their signature on the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Eligible participants must not have a history of psychiatric or neurological disorders, as judged by the investigator, which may impact the evaluation of the study's efficacy;
  • Participants must not have a history of seizures or prior episodes of epilepsy;
  • The presence of metallic foreign objects within the cranial structure or metallic cardiac implants;
  • Participants must not have a diagnosis of organic brain disease, nor a history of significant cranial trauma or neurosurgical intervention;
  • Participants received electroconvulsive therapy or other physical therapies (such as transcranial magnetic stimulation therapy); The researcher evaluated the individual's mental state and determined it to present a significant risk of suicidal ideation or behavior;
  • Pregnant or breastfeeding;
  • Participants who are concurrently engaged in other clinical interventional trials;
  • Participants presenting with other circumstances that the investigator deems unsuitable for the intervention being studied
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Amygdala TI

    Right amygdala Temporal Interference (TI) stimulation with 100 frequency difference, 20 minutes per day for 5 days.

    Device: Nervio-X

  • Experimental
    dLPFC TI

    L_dLPFC TI Temporal Interference (TI) stimulation with 10 frequency difference, 20 minutes per day for 5 days.

    Device: Nervio-X

Interventions

  • DeviceNervio-X

    An 8-channel TIS device developed by NEURODOME Corporation.

06

What researchers measure

Primary outcomes

  1. HAMD-17

    Time frame: Baseline, after treatment, 1 week, 4 weeks and 8 weeks

  2. HAMA

    Time frame: Baseline, after treatment, 1 week, 4 weeks and 8 weeks

  3. MADRS

    Time frame: Baseline, after treatment, 1 week, 4 weeks and 8 weeks

  4. PHQ-A

    Time frame: Baseline, after treatment, 1 week, 4 weeks and 8 weeks

  5. GAD-7

    Time frame: Baseline, after treatment, 1 week, 4 weeks and 8 weeks

  6. SHAPS

    Time frame: Baseline, 4 weeks and 8 weeks

  7. PSQI

    Time frame: Baseline, 4 weeks and 8 weeks

  8. SF-36

    Time frame: Baseline and 8 weeks

  9. WHOQOL-BREF

    Time frame: Baseline and 8 weeks

  10. ARI

    Time frame: Baseline and 8 weeks

  11. OSI

    For use when the patient exhibits self-harming behavior

    Time frame: Baseline, 4 weeks and 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Apr 2025, 11 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 11 months is below that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2024
First posted
Jun 11, 2024
StartActual
May 27, 2024
Primary completionEst.
Apr 28, 2025
CompletionEst.
Apr 28, 2025
Last update
Jun 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06452849
Lead sponsor
Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University
Collaborators
Ruijin Hospital
Responsible party
huangjingjing (Chief Physician, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University) — Principal investigator
First posted
Jun 11, 2024
Start date
May 27, 2024
Primary completion
Apr 28, 2025 (estimated)
Completion
Apr 28, 2025 (estimated)
Last update
Jun 11, 2024

Study contacts

JINGJING HUANG, MD PhD
Contact
jjhuang_att@163.com
021-68306699*1222
Chencheng Zhang, MD PhD
Contact
i@cczhang.org
18217122884

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion